While some biotechnologies charge ahead at the forefront of their fields, others limp along at the rear. While many limpers have been eclipsed by more effective technologies, others have value and simply need help to realize their potential.

SkyePharma plc acquired a limper, Geomatrix delivery technology, when it purchased privately-held Jagotec AG in 1996. SkyePharma (LSE:SKP; SKYE) added needed financing and altered the market focus for Geomatrix. Last week the technology added a fifth regulatory approval, in several European countries, as part of partner Sanofi-Synthelabo S.A.'s Xatral OD